Abaloparatide Research

Kendler DL, Habert J, Khan AA, Kherani RB, Kim S, Kovacs CS et al.

Although patients with remote or brief prior exposure to osteoporosis treatments are strictly not "treatment naive," osteoporosis treatment effects on bone mineral density and bone turnover resolve over time. It would therefore be useful to categorize patients with remote or brief ...

Jain H, Sarikonda A, Ahluwalia R, Zakieh O, Montgomery A, Navid W et al.

Though the use of anabolic bone agents has proven effective in adult spinal deformity (ASD) surgery, prescription and approval of these medications remains a challenge. In osteopenic/osteoporotic patients undergoing ASD surgery, we sought to determine the impact of a bone optimization clinic on: ...

Joko I, Uchida M, Hino M, Miyaoka S, Tanaka M, Kasuga K et al.

We report a case of a 64-year-old woman who developed a 4-parts shoulder fracture-dislocation with peripheral nerve injury by the displaced fragment, during abaloparatide treatment. Following shoulder hemiarthroplasty, bone union at the greater tuberosity was achieved on postoperative day 16, wit...

Bonifacio M, Ruggiero M, Lucchetti L, Musorrofiti MG, La Cava G, Chiappetta A et al.

Background/Objectives: Abaloparatide is an osteoanabolic therapy used in patients at high risk of fracture; however, the breadth of evidence across routes, comparators, and sequential strategies has not yet been comprehensively summarized. This study aimed to evaluate the efficacy and safety of a...

Lee KI, Chen JH, Chen KH

Osteoporosis is a prevalent skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased fracture risk, particularly in aging populations. Postmenopausal osteoporosis (PMOP) remains the most common primary form and results from abrupt estrogen de...

Ara T, Iqbal Z, Jain S, Sheikh AA, Vohora D

Abaloparatide, a 34-amino acid synthetic peptide analog of parathyroid hormone-related protein (PTHrP), was approved for treating postmenopausal osteoporosis in high-risk individuals or those resistant to existing drugs. This study aimed to investigate the impact of abaloparatide (20 µg...

Padlina I, Trombetti A, Ferrari S, Biver E

In 2025, osteoporosis management in Switzerland benefited from the introduction of abaloparatide, an anabolic PTHrP analogue that effectively reduces the risk of vertebral and non-vertebral fractures, with reimbursement criteria identical to those of romosozumab. Zoledronate, administered prevent...

Gifre L, Fusaro M, Lloret MJ, Massó E, Peris P, Nogués X et al.

Osteoporosis and fragility fractures are among the most prevalent and clinically significant complications in patients with chronic kidney disease (CKD), particularly in stages G4-G5 and in those undergoing dialysis (G5D). These skeletal disorders are associated with markedly increased morbidity ...

Jia M, Chen Z, Zhou H, Jiang H, Zhang Y, Liu Y et al.

Bone defect repair remains a significant challenge faced in clinical practice. Bone tissue engineering has emerged as an effective approach for bone defect repair due to its ample donor source and remarkable repair efficacy. In this study, we combined Abaloparatide (ABL) with bone marrow-derived ...

Valleenukul T, Songpatanasilp T, Jaisamrarn U, Anuraklekha S, Srinonprasert V, Chaiamnuay S et al.

Atypical femoral fractures (AFFs) are a rare but serious complication of prolonged anti-resorptive therapy for osteoporosis. This study aimed to develop consensus-based recommendations for the clinical management of AFFs across the Asian Federation of Osteoporosis Societies (AFOS), for harmonizin...

Lu KH, Wang SI, Yang SF

To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with h...

Suarez-Nieto MV, Malacon K, Fox A, Lopez Isidro MC, Wadhwa H, Hu SS et al.

Background: Osteoporosis and low bone mineral density are highly prevalent among patients undergoing spinal fusion, contributing to higher rates of hardware failure, revision surgery, and poor postoperative outcomes. Despite clear risks, perioperative screening and treatment for osteoporosis rema...

Wu H, Liu Y, Zhang J, Sen B, Curtis JR

Despite guideline recommendations, pharmacologic treatment after osteoporotic fracture remains suboptimal.To identify individual and community factors associated with osteoporosis (OP) treatment after major osteoporotic fracture, and to investigate osteoporosis treatment patterns before and after...

Bikle D

Fractures engender a multimillion dollar medical cost to society with substantial morbidity and mortality for the patients. In long bones fracture repair takes place at 3 distinct sites: intramembranous bone formation along the outer surface of the periosteum, endochondral bone formation bridging...

Sølling AS, Langdahl BL, Cosman F

Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimposed genetic and environmental factors. Many patients with osteoporosis are not diagnosed, and the majority are not treated. Current therapies for osteoporosis include anti...

Sendhil SR, Cadarette SM, Aggarwal S, Oganisian A, Zullo AR, Berry SD et al.

Denosumab is an effective osteoporosis therapy, but discontinuing treatment can result in rebound-associated fractures. Guidelines recommend starting follow-on osteoporosis therapy within 6 months of the last dose, but real-world practice is under-described. We found only 6.0% of patients in...

Pal R, Yadav U, Banerjee M, Prasad TN, Bhadada SK

To synthesize evidence on the efficacy of osteoanabolic therapies (teriparatide, abaloparatide, romosozumab) in adults with type 2 diabetes mellitus (T2D), focusing on changes in bone mineral density (BMD) and fractures, and to explore whether responses differ between people with and without diab...

Stumpf U, Kurth A

Teriparatide and abaloparatide are osteoanabolic agents that promote the formation of new bone by activating the PTH1 receptor, significantly reducing the risk of fractures, particularly vertebral fractures. Romosozumab works by inhibiting sclerostin. To maintain the therapeutic benefit after ost...

Khalid SI, Wang R, Abou-Mrad T, Massaad E, Arena JD, Ghenbot Y et al.

Osteoporosis increases the risk of postoperative complications and reoperation following spinal fusion due to reduced bone quality. Bone-strengthening medications are frequently employed to mitigate these risks. This study evaluates the impact of osteoporosis and osteoporosis medications on the i...

Kızıldağ A, Alpan AL, Özdoğan Z, Özmen Ö, Zavrak N, Terzi M et al.

Abaloparatide is a second-generation osteoporosis drug that prevents bone loss and stimulates bone fromation. This study evaluated the effects of abaloparatide treatment on alveolar bone loss (ABL) in osteoporotic rats with periodontitis by immunohistochemical and microcomputed tomography (micro-...